Compositions and methods having mt1 receptor activity
AssigneeAGI Therapeutics Research Ltd.
InventorsJohn Devane, John Kelly, Mary Martin
Life of this patent
Estimating the term…
Abstract
The present invention is directed to compositions and to methods comprising a composition comprising a therapeutically effective amount of a pharmaceutically active agent such as (R)-verapamil, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein the composition treats and/or manages at least one condition having MT1 receptor activity and releases the pharmaceutically active agent, a derivative thereof or a pharmaceutically acceptable salt thereof to exhibit a primary activity on the MT1 receptor such as, exhibiting at least five times more activity on the MT1 receptor compared with the MT2 receptor.
Claims41
A composition comprising a therapeutically effective amount of at least one pharmaceutically active agent, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein the composition treats at least one condition having MT1 receptor activity in a subject in need thereof and releases the pharmaceutically active agent, a derivative thereof or a pharmaceutically acceptable salt thereof to exhibit a primary activity on the MT1 receptor.
A method comprising administering a composition comprising a therapeutically effective amount of a pharmaceutically active agent, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein the composition treats at least condition having MT1 receptor activity in a subject in need thereof and releases the pharmaceutically active agent, a derivative thereof or a pharmaceutically acceptable salt thereof to exhibit a primary activity on the MT1 receptor.
A method comprising administering a composition comprising a therapeutically effective amount of a pharmaceutically active agent, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein the composition manages at least one condition having MT1 receptor activity in a subject in need thereof and releases the pharmaceutically active agent, a derivative thereof or a pharmaceutically acceptable salt thereof to exhibit a primary activity on the MT1 receptor.
Dependencies are inferred from the claim text.